DMG Deutsche Malaria GmbH is dedicated to fighting malaria. The company is using Fosmidomycin to enforce existing therapies as well as developing new antimalarial therapeutic alternatives.
The privately owned Hamburg, Germany based company has build a highly promising record of research currently culminating in the successful combination of Fosmidomycin and Piperaquine in Phase II studies in Africa.
Partners are wellcome to join these efforts to speed up the next steps of the study program with the goal to bring relevant antimalarial therapeutic options to the market.
DMG Deutsche Malaria GmbH has been or is supported by Medicines for Malaria Venture (MMV) – a not for profit organisation funded by the Bill And Melinda Gates Foundation, European and Developing Countries Clinical Trials Programme (EDCTP) and World Health Organisation (WHO).